Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

AH Hansma, H.J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H.M. Pinedo, K. Hoekman

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1695-1701
JournalAnnals of Oncology
Volume16
Issue number10
DOIs
Publication statusPublished - 2005

Cite this